...COVID-19 miss by an IL-6 inhibitor, Actemra tocilizumab...

...unit of Roche (SIX:ROG; OTCQX:RHHBY) said Friday that the Phase III EMPACTA trial of Actemra tocilizumab...
...are secondary endpoints. TARGETSIL-6 – Interleukin-6 Stephen Hansen RoActemra (Brand), Actemra (Brand), RG1569 (Compound #), R1569 (Compound #), tocilizumab...

...three other potential COVID-19 treatments — azithromycin, tocilizumab...
...Brand), RG1569 (Compound #), R1569 (Compound #), tocilizumab...

...ventilation. Dexamethasone’s success had contrasted sharply with July’s Phase III disappointments for anti-IL-6 mAbs Actemra tocilizumab...

...actually donated drugs -- so Roche donated tocilizumab...
...And particularly -- take the example of tocilizumab...
...more patients randomized in recovery trial to tocilizumab...

...CEO Severin Schwan noted that the Phase III failures of IL-6 inhibitors including Roche’s Actemra tocilizumab...

...Phase III in September. IL-6 86’d BARDA has stopped supporting development of anti-IL-6 mAbs Actemra tocilizumab...
...#), REGN88 (Compound #), sarilumab (Generic) RoActemra (Brand), Actemra (Brand), RG1569 (Compound #), R1569 (Compound #), tocilizumab...

...common side effect of treatment with CAR T therapies, and IL-6 inhibitors such as Actemra tocilizumab...

...rather than targeting that specific cytokine -- may offer a more effective treatment. Actemra tocilizumab...
...Interleukin-6 Elizabeth S. Eaton, Staff Writer RoActemra (Brand), Actemra (Brand), RG1569 (Compound #), R1569 (Compound #), tocilizumab...

...has disappointed -- failing a previous trial in severe patients -- another anti-IL-6 mAb, Actemra tocilizumab...